Krystal Biotech (KRYS) Competitors $143.01 +1.66 (+1.17%) Closing price 07/3/2025 03:17 PM EasternExtended Trading$146.50 +3.49 (+2.44%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KRYS vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and VRNAShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation. Do institutionals & insiders have more ownership in SMMT or KRYS? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Comparatively, 13.7% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor SMMT or KRYS? In the previous week, Summit Therapeutics had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Summit Therapeutics and 19 mentions for Krystal Biotech. Summit Therapeutics' average media sentiment score of 0.53 beat Krystal Biotech's score of 0.17 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, SMMT or KRYS? Krystal Biotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K25,829.00-$221.32M-$0.34-71.60Krystal Biotech$290.52M14.23$89.16M$4.1634.38 Is SMMT or KRYS more profitable? Krystal Biotech has a net margin of 37.17% compared to Summit Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 14.64% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -62.87% -51.61% Krystal Biotech 37.17%14.64%13.28% Which has more volatility and risk, SMMT or KRYS? Summit Therapeutics has a beta of -1.01, suggesting that its stock price is 201% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do analysts prefer SMMT or KRYS? Summit Therapeutics presently has a consensus price target of $34.67, indicating a potential upside of 42.40%. Krystal Biotech has a consensus price target of $211.13, indicating a potential upside of 47.63%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryKrystal Biotech beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.08B$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio34.3821.5627.4020.24Price / Sales14.23281.35419.60118.25Price / Cash30.4841.9536.6357.47Price / Book4.357.518.085.67Net Income$89.16M-$55.05M$3.16B$248.47M7 Day Performance2.97%4.71%2.84%3.32%1 Month Performance8.32%4.89%3.69%5.20%1 Year Performance-19.46%5.82%35.30%21.35% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.5326 of 5 stars$143.01+1.2%$211.13+47.6%-19.5%$4.08B$290.52M34.38210Trending NewsAnalyst RevisionSMMTSummit Therapeutics2.5435 of 5 stars$20.39-0.8%$35.09+72.1%+253.3%$15.27B$700K-59.97110Trending NewsAnalyst ForecastOptions VolumeTrading HaltedITCIIntra-Cellular Therapies0.983 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.5825 of 5 stars$20.68-2.3%$39.17+89.4%-18.8%$13.57B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8598 of 5 stars$15.31+0.5%$16.95+10.7%-0.9%$12.71B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.5459 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017Analyst ForecastVTRSViatris3.2678 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.74B3.5832,000QGENQiagen4.0591 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3855 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.7305 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6467 of 5 stars$97.05+2.9%$101.10+4.2%+480.4%$8.03B$42.28M-48.5330Positive NewsAnalyst Forecast Related Companies and Tools Related Companies SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives BPMC Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRYS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
